Welcome to our dedicated page for Protagonist Ther news (Ticker: PTGX), a resource for investors and traders seeking the latest updates and insights on Protagonist Ther stock.
Protagonist Therapeutics develops peptide-based therapeutics using a proprietary discovery platform, with programs spanning inflammation and immunology, hematology and metabolic disease. Company news centers on ICOTYDE™ (icotrokinra), an oral IL-23 receptor-targeted peptide approved for moderate-to-severe plaque psoriasis, and rusfertide, a hepcidin mimetic peptide for polycythemia vera developed with Takeda.
Recurring updates also cover collaboration economics with Johnson & Johnson's Janssen Biotech and Takeda, clinical and regulatory milestones, R&D spending on wholly owned discovery programs, financial results, investor conference participation and equity-based inducement awards under Nasdaq rules.
Protagonist Therapeutics (NASDAQ:PTGX) has announced its participation in the BTIG Virtual Biotechnology Conference 2024. The event is scheduled for August 5-6, 2024. Dinesh V. Patel, Ph.D., the company's President and CEO, will take part in a fireside chat on Tuesday, August 6 from 2:00-2:35 P.M. EDT.
In addition to the fireside chat, Protagonist's team will be available for one-on-one meetings during the conference. Interested parties are encouraged to contact their BTIG representative to arrange meetings with the Protagonist team.
Protagonist Therapeutics presented updated long-term follow-up results from the Phase 2 REVIVE study of rusfertide at the EHA2024 Congress. The study shows that rusfertide provides durable control of hematocrit levels below 45% for up to 3 years in patients with polycythemia vera. Additionally, it reduced the need for phlebotomies and normalized serum ferritin levels without new safety concerns. As of April 9, 2024, 81% of patients remain on treatment, with many transitioning to the THRIVE study for an additional two years. The study reports a stable safety profile, despite a small increase in localized, early-stage skin cancer cases among high-risk patients.
Protagonist Therapeutics announced its participation at the Jefferies Global Healthcare Conference 2024, scheduled for June 4-6 in New York City.
Dinesh V. Patel, Ph.D., President and CEO, will engage in a fireside chat on June 5 at 11:00-11:25 A.M. EDT and hold one-on-one meetings with participants.
The fireside chat will be webcasted live and a replay will be available for 90 days on the company's website.
Protagonist Therapeutics (NASDAQ:PTGX) announced that new data from its rusfertide Phase 2 REVIVE study will be presented at the European Hematology Association (EHA) Congress scheduled for June 13-16, 2024, in Madrid, Spain. The presentation will focus on long-term results, specifically hematocrit control and therapeutic phlebotomy frequency in patients with Polycythemia Vera. Additionally, an abstract published at the event will highlight the absence of QTc prolongation in a thorough QT/QTc study with healthy subjects. Key figures involved in the presentations include Dr. Kristen M. Pettit from the University of Michigan and Nishit Modi, SVP of Clinical Pharmacology at Protagonist.
Protagonist Therapeutics, Inc. announced that their President and CEO, Dinesh V. Patel, Ph.D., will participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event in New York City on May 13-14, 2024.
Protagonist Therapeutics reported strong financial results for Q1 2024 and significant corporate developments, including a partnership with Takeda for rusfertide, completion of Phase 3 trials for JNJ-2113, and upcoming milestones for the oral IL-17 program. The company's cash reserves remain healthy, with license and collaboration revenue of $255 million.
Summary not available.
Summary not available.
Summary not available.
Summary not available.